Oyster Point Pharma, Inc.
Oyster Point Pharma, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on innovative therapies for ocular surface diseases. Founded in 2015, the company has rapidly established itself in the ophthalmic industry, particularly with its flagship product, Tyrvaya™ (varenicline solution), which addresses dry eye disease through a unique mechanism of action. With a commitment to advancing patient care, Oyster Point Pharma has achieved significant milestones, including successful clinical trials and regulatory approvals. The company operates primarily in the US but aims to expand its reach globally. Recognised for its dedication to research and development, Oyster Point Pharma continues to enhance its market position by delivering effective solutions that improve the quality of life for patients suffering from eye-related conditions.
DitchCarbon Score
How does Oyster Point Pharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Oyster Point Pharma, Inc.'s score of 45 is lower than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Oyster Point Pharma, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a merged entity and inherits its climate commitments and emissions data from its parent organisation, Viatris Inc. As of now, there are no documented reduction targets or significant climate initiatives directly attributed to Oyster Point Pharma. However, the climate commitments and performance metrics are cascaded from Viatris Inc., which is actively engaged in sustainability efforts. Oyster Point Pharma's climate strategy aligns with industry standards, although specific details regarding emissions scopes (Scope 1, 2, or 3) and reduction achievements are not provided. The absence of direct emissions data suggests that the company may still be in the process of establishing its own climate action framework. In summary, while Oyster Point Pharma, Inc. does not currently report specific emissions figures or reduction targets, it is positioned within a corporate family that prioritises climate commitments through Viatris Inc.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 299,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 354,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | - |
| Scope 3 | - | - | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Oyster Point Pharma, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
